1, cell therapy or normalizing spina bifida fetuses
3 spina bifida fetuses born after cell therapy at UC Davis Health. This is a landmark clinical trial, the world’s first unique method combining surgery with stem cells, performed while the fetus is still developing in the mother’s womb, to improve people with this birth defect, researchers say The prognosis of children with disease.
The clinical trial, officially titled “CuRe Trial: Cell Therapy for Intrauterine Myelomeningocele Repair”, will begin in Spring 2021 and will see 35 patients treated. (Science and Technology Daily)
2, The world’s first allogeneic mesenchymal stem cell new drug for IPF clinically launched
Recently, Shanghai Laifu Medical Technology Co., Ltd. has completed the research and development task of “Human Umbilical Cord Mesenchymal Stem Cell Injection”. “An open clinical study to explore the safety, tolerability and preliminary efficacy of human umbilical cord mesenchymal stem cell injection in the treatment of idiopathic pulmonary fibrosis (IPF)” has been launched in Shanghai Sixth People’s Hospital, and will be simultaneously It was launched in Zhongshan Hospital Affiliated to Fudan University and Shanghai Chest Hospital. This means that the world’s first allogeneic umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis, a new drug registration clinical study officially started. Through the cooperation of all parties, it is believed that early exploratory studies such as safety observation and efficacy indicators can be completed soon and enter the third clinical phase. (arterial network)
3. Mersk & Co.’s PD-1 inhibitor Kreida®️ was approved for new indications for liver cancer treatment in China
Recently, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: Keruida®️) has been approved by the China National Medical Products Administration (NMPA) as a single drug for Treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib or oxaliplatin-containing chemotherapy. The approval of the new indication is based on data from the Phase III clinical trial KEYNOTE-394. (PR Newswire)
4.Omicron BF.7 variant appeared again in Inner Mongolia, and WHO warned that “may become mainstream within a few weeks”
According to the daily economic news, Ulanhot City, Inner Mongolia introduced at the press conference on the prevention and control of the new crown pneumonia epidemic held on October 9th. A total of 1 local confirmed case of new coronary pneumonia, 7 asymptomatic infections, and 7 mixed-tube samples were found to have abnormal test results. After genetic sequencing, the new coronavirus infected by the current round of epidemic cases in Ulanhot belongs to the evolutionary branch of Omicron BF.7, which is highly homologous to the epidemic in which the first confirmed case occurred in Hohhot on September 28. The latter is the first local epidemic caused by BF.7 in China.
BF.7 is the abbreviation of BA.220.127.116.11, the third-generation subtype derived from the Omicron BA.5 variant (another subtype derived from BA.5 is BA. .2.75). The WHO had previously issued a warning that BF.7 was spreading globally and “may become mainstream within a few weeks.” According to data from the US Centers for Disease Control and Prevention, the percentage of BF.7 strains has risen to 4.6% in a short period of time since monitoring began, making it the third-highest mutant strain in the United States. In addition, in Europe, BF.7 has accounted for 25% of infected people in Belgium; Germany, France and Denmark account for about 10%. (Daily Economic News)